First Prescription Drug Reaches European Market With Advancia
Six months after the successful industrialization of Nemera’s next-generation nasal spray pump, Advancia is on the European market with an intranasal corticosteroid suspension treating allergic rhinitis. It is also under registration process in Asia for other corticosteroid drugs.
Nemera has invested more than 10 million euros in R&D and manufacturing in its Le Tréport plant (France) to launch the only user-independent multi-dose nasal spray system on the market, with 45 million units’ annual capacity. Advancia embodies a major breakthrough in nasal drug delivery by providing patients with a user-independent device, ideal for topical and systemic preserved drugs, in a user-friendly package.
Patients non-compliant with their therapy can result in ineffective treatment or worse, in harmful effects in patients.
The Advancia new user-independent nasal spray guarantees a consistent dose and spray, irrespective of the way the patient uses it. This user-independent device delivers an excellent dose consistency, exceeding the most stringent regulatory requirements. Moreover, with its anti-clogging technology, the system ensures spray delivery even with formulations that tend to crystallize. As a result, patients are not required to clean the actuator after each use. The extended prime retention, up to several months, offers a unique solution for on-and-off treatments; the patients do not have to re-prime the pump to ensure full delivery of the dose after multiple weeks of non-use; this also limits drug waste (no spray loss). All these features improve patient compliance.
Advancia® offers several major advantages, such as user-independence, mechanical closing tip to prevent problems due to clogging, excellent dose consistency, long prime retention, no metal part in contact with the formulation, and compatible with FEA 20-mm crimp-on neck finish bottles (plastic or glass).
Nemera is one of the world leaders in the design, development, and manufacturing of drug delivery solutions. Its expertise covers all five modes of delivery: Nasal/Buccal/Auricular (spray pumps, actuators, valves, etc.), Ophthalmic (preservative-free droppers), Pulmonary (pMDIs, DPIs), Dermal /Transdermal (airless & atmospheric dispensers), and Parenteral (autoinjectors, pens, and safety devices). Nemera provides solutions for the pharmaceutical industry, including standard innovative products, the development of proprietary devices and contract manufacturing. The Advancia innovative project is co-financed by the European Union. Europe is committed in Normandy with the European Regional Development Fund (FEDER). For more information, visit www.nemera.net.
Total Page Views: 950
